Metformin and empagliflozin combination modulate macrophage inflammatory gene expression

Arefin, Adittya; Gage, Matthew C

Abstract

Type-2 Diabetes Mellitus is a complex, chronic illness characterized by persistent high blood glucose levels. Patients can be described anti diabetes drugs as single agents or in combination depending on the severity of their condition. Metformin and empagliflozin are two commonly prescribed anti-diabetes drugs which reduce hyperglycemia, however their direct effects on macrophage inflammatory responses alone or in combination are unexplored. Here we show that metformin and empagliflozon elicit proinflammatory responses on mouse bone-marrow derived macrophages which are reduced when added in combination.

Citation

Arefin, A., & Gage, M. C. (2023). Metformin and empagliflozin combination modulate macrophage inflammatory gene expression. International Journal of Molecular Sciences, https://doi.org/10.3390/ijms24054785

• Journal Article Type: Article
• Acceptance Date: Feb 23, 2023
• Online Publication Date: Mar 1, 2023
• Publication Date: Mar 1, 2023
• Deposit Date: Mar 9, 2022
• Publicly Available Date: Mar 7, 2023
• Journal: International Journal of Molecular Sciences
• Print ISSN: 1661-6596
• Electronic ISSN: 1422-0067
• Publisher: MDPI
• Peer Reviewed: Peer Reviewed
• DOI: https://doi.org/10.3390/ijms24054785
• Keywords: Macrophage; diabetes; insulin resistance; metformin; empagliflozin, combinations; anti-diabetes drugs
• Publisher URL: https://www.mdpi.com/journal/ijms